蕁麻疹治療薬の世界市場2018-2022

◆英語タイトル:Global Urticaria Drugs Market 2018-2022
◆商品コード:IRTNTR23857
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月20日
◆ページ数:99
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、蕁麻疹治療薬の世界市場について調査・分析し、市場概要、市場環境、蕁麻疹治療薬市場規模、薬の種類別(抗ヒスタミン薬、抗炎症剤、スルホン、生物製剤)分析、用途別(急性蕁麻疹、慢性蕁麻疹)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・蕁麻疹治療薬の世界市場概要
・蕁麻疹治療薬の世界市場環境
・蕁麻疹治療薬の世界市場動向
・蕁麻疹治療薬の世界市場規模
・蕁麻疹治療薬の世界市場:業界構造分析
・蕁麻疹治療薬の世界市場:薬の種類別(抗ヒスタミン薬、抗炎症剤、スルホン、生物製剤)
・蕁麻疹治療薬の世界市場:用途別(急性蕁麻疹、慢性蕁麻疹)
・蕁麻疹治療薬の世界市場:地域別市場規模・分析
・蕁麻疹治療薬の北米市場規模・予測
・蕁麻疹治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・蕁麻疹治療薬のアジア太平洋市場規模・予測
・蕁麻疹治療薬の主要国分析
・蕁麻疹治療薬の世界市場:意思決定フレームワーク
・蕁麻疹治療薬の世界市場:成長要因、課題
・蕁麻疹治療薬の世界市場:競争環境
・蕁麻疹治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
Urticaria is a vastly prevalent disorder resulting in high medical consultations globally. The increase in risk factors for urticaria like latent infectious, chronic inflammatory diseases, autoreactivity and alcohol consumption. Though the incident is increasing, and it is negatively impacting the quality of life of the people, most patients are undertreated due to challenges in affordability of drugs and low access to healthcare due to social stigma. Technavio’s analysts have predicted that the urticaria drugs market will register a CAGR of over 10% by 2022.
Market Overview
Guidelines for management of urticaria patients
The management guidelines include clinical classification, etiology, investigations, diagnosis, treatment guidance along with special sections on children suffering from urticaria and the use of antihistamines in pregnant women or breastfeeding women.
High cost of urticaria management
The high medication costs along with the indirect costs are expected to put low- income patients at danger for suboptimal treatment and an increased burden due to poorly controlled disease.
For the detailed list of factors that will drive and challenge the growth of the urticaria drugs market during the 2018-2022, view our report.
Competitive Landscape
The global urticaria drugs market is moderately concentrated and the market being in a growth phase, the competition among companies is intense. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Urticaria pipeline analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: BY TYPE OF DRUG
• Segmentation by type of drug
• Antihistamines
• Anti-inflammatory agents
• Sulfones
• Biologics
PART 09: MARKET SEGMENTATION BY APPLICATION
• Segmentation by application
• Comparison by application
• Acute urticaria – Market size and forecast 2017-2022
• Chronic urticaria – Market size and forecast 2017-2022
• Market opportunity by application
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• EMEA – Market size and forecast 2017-2022
• Americas – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
• Introduction of biologics for the treatment of urticaria
• International guidelines for diagnosis and management of urticaria
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche (Genentech)
• JDP Therapeutics
• Meiji Holdings
• Novartis
• Taiho Pharmaceutical
PART 17: APPENDIX
• List of abbreviations
PART 18: EXPLORE TECHNAVIO



Exhibit 01: Parent market
Exhibit 02: Global dermatological drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs for urticaria
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Application – Market share 2017-2022 (%)
Exhibit 20: Comparison by application
Exhibit 21: Acute urticaria – Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Acute urticaria – Year-over-year growth 2018-2022 (%)
Exhibit 23: Chronic urticaria – Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Chronic urticaria – Year-over-year growth 2018-2022 (%)
Exhibit 25: Market opportunity by application
Exhibit 26: Customer landscape
Exhibit 27: Global – Market share by geography 2017-2022 (%) 57
Exhibit 28: Regional comparison 58
Exhibit 29: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 30: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 31: Top 3 countries in EMEA
Exhibit 32: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in Americas
Exhibit 35: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 36: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Market opportunity
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: F. Hoffmann-La Roche (Genentech) – Overview
Exhibit 45: F. Hoffmann-La Roche (Genentech) – Business segments
Exhibit 46: F. Hoffmann-La Roche (Genentech) – Organizational developments
Exhibit 47: F. Hoffmann-La Roche (Genentech) – Geographic focus
Exhibit 48: F. Hoffmann-La Roche (Genentech) – Segment focus
Exhibit 49: F. Hoffmann-La Roche (Genentech) – Key offerings
Exhibit 50: JDP Therapeutics – Overview
Exhibit 51: JDP Therapeutics – Business segments
Exhibit 52: JDP Therapeutics – Organizational developments
Exhibit 53: JDP Therapeutics – Key offerings
Exhibit 54: Meiji Holdings – Overview
Exhibit 55: Meiji Holdings – Organizational developments
Exhibit 56: Meiji Holdings – Key offerings
Exhibit 57: Novartis – Overview
Exhibit 58: Novartis – Business segments
Exhibit 59: Novartis – Organizational development
Exhibit 60: Novartis – Geographic focus
Exhibit 61: Novartis – Segment focus
Exhibit 62: Novartis – Key offerings
Exhibit 63: Taiho Pharmaceutical – Overview
Exhibit 64: Novartis – Organizational developments
Exhibit 65: Taiho pharmaceutical – Key offerings




【掲載企業】

F. Hoffmann-La Roche (Genentech)、JDP Therapeutics、Meiji Holdings、Novartis、Taiho Pharmaceutical

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[蕁麻疹治療薬の世界市場2018-2022]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆